Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas. - Wikidata - awgldk - TriplyDB

Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas.

Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas.

http://www.wikidata.org/entity/Q37225747

about

Cabozantinib for progressive metastatic medullary thyroid cancer: a review Molecular basis of medullary thyroid carcinoma: the role of RET polymorphisms Recent Updates on the Management of Medullary Thyroid Carcinoma Cabozantinib in progressive medullary thyroid cancer.Predominant RET Germline Mutations in Exons 10, 11, and 16 in Iranian Patients with Hereditary Medullary Thyroid Carcinoma.Thyroid oncology.Thyroid cancer: pathogenesis and targeted therapy Advanced medullary thyroid cancer: pathophysiology and management Retrospective analysis of 140 cases of medullary thyroid carcinoma followed-up in a single institution.2012 European thyroid association guidelines for genetic testing and its clinical consequences in medullary thyroid cancer In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.Differences in the transcriptome of medullary thyroid cancer regarding the status and type of RET gene mutations.How to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid Cancer Novel therapies for thyroid cancer.Treatment of advanced thyroid cancer: role of molecularly targeted therapies.Current Advances in Thyroid Cancer Management. Are We Ready for the Epidemic Rise of Diagnoses?Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer.Medullary Thyroid Cancer: Clinical Characteristics and New Insights into Therapeutic Strategies Targeting Tyrosine Kinases.Medullary Thyroid Carcinoma: Recent Advances Including MicroRNA Expression.Combination chemotherapy with 5-fluorouracil and dacarbazine in advanced medullary thyroid cancer, a possible alternative?Lymph Node Metastases in Papillary and Medullary Thyroid Carcinoma Are Independent of Intratumoral Lymphatic Vessel Density.Reduced Retinoblastoma Protein Expression Is Associated with Decreased Patient Survival in Medullary Thyroid Cancer.Hereditary and familial thyroid tumours.Refractory thyroid carcinoma: which systemic treatment to use?New insights in the molecular signature of advanced medullary thyroid cancer: evidence of a bad outcome of cases with double RET mutations.Diversity of mutations in the RET proto-oncogene and its oncogenic mechanism in medullary thyroid cancer.Extended RET gene analysis in patients with apparently sporadic medullary thyroid cancer: clinical benefits and cost.Identification and characterization of two novel germline RET variants associated with medullary thyroid carcinoma.High prevalence of exon 8 G533C mutation in apparently sporadic medullary thyroid carcinoma in Greece.

P2860

Q26851709-394F20AD-B6AE-49E1-9AF5-8FA6F3CD34D6 Q27010044-3F6B4530-8C0D-4095-86A9-68AF14A4867A Q28066911-ADA835A5-7D2A-49B8-9576-6763E2ACF007 Q34185084-DCAA2139-2731-45EF-9DE9-C7BE495E5A42 Q35098936-0E492110-3BBE-4C7E-BF78-4B8CAD8FBC27 Q35326218-BE4697FA-8CE1-4CB4-9598-F64C2030C41D Q36328045-C2387253-024C-47AA-A401-6C73B7F00C72 Q36857218-F5A6D7DE-F64C-4D38-AFF2-D5ABCE5843E4 Q36954521-69164AE8-BA76-4FD5-96CD-8861D17ECA72 Q37290956-73CE44CE-3C14-43CD-9E2E-33B1FE053192 Q37403891-DF7FAC8D-7299-4481-AB4D-BA1E8740D887 Q37633558-AC2C4CAE-EE70-4688-B923-E5ECCC0CEBDB Q37902072-812C48A6-3482-4D3C-A71D-DD5829130A42 Q38260495-290F91C9-911C-432B-8C34-8B5780AEF5CB Q38579925-226FC9B8-0E41-490D-A5A7-A2D3A0D533B0 Q38614394-55962AF1-28AE-4235-9ED8-91738AC9F031 Q38625034-308ED688-B516-4D24-A092-48429086A667 Q38683133-350C27F5-F468-4F8E-843F-BFE3E66F73F7 Q38931460-D1CB7FCF-BDA4-48F6-A59C-59867049BF1A Q40757352-1470B845-61AC-4437-BF7A-2F2C41EA8E75 Q41641233-1AE2FB59-D534-4C84-8EA3-9FC398BEA546 Q47438629-664A4D20-44A6-453C-923A-8AAC84F3E6BA Q48120117-70DBA3D8-3915-4088-B8C7-DC0D01AAFE72 Q49335901-F33CB07B-4211-4003-A467-529950F3B4BF Q52984965-92010C50-5B37-4934-8738-D17A4B6EB052 Q53368705-1AF5B331-A8F8-48D7-9D82-1869111B4B8D Q54003420-C7992E6D-3569-4A81-AFEE-871AFBDF29EA Q54287597-2A6F4551-52B9-47E9-9A03-2F6B953660D8 Q54505944-573149F3-8410-461A-8458-C07994E61940

P2860

Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas.

http://www.wikidata.org/entity/Q37225747

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 28 April 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Correlation of RET somatic mut ...... medullary thyroid carcinomas.

@en

Correlation of RET somatic mut ...... medullary thyroid carcinomas.

@nl

type

label

Correlation of RET somatic mut ...... medullary thyroid carcinomas.

@en

Correlation of RET somatic mut ...... medullary thyroid carcinomas.

@nl

prefLabel

Correlation of RET somatic mut ...... medullary thyroid carcinomas.

@en

Correlation of RET somatic mut ...... medullary thyroid carcinomas.

@nl

P1433

Q37225747-84EB5F4D-B969-427D-9600-3D145127D558

P1476

Q37225747-8275FDBA-919B-4C73-BDD0-B3B61BF68403

P2093

Q37225747-1550477C-28DF-49B6-9ECD-B4A03E5F218E

Q37225747-4ABF1189-1118-4BC3-ACF5-2450664BE53A

Q37225747-5A6B9DAB-0343-4A07-A428-5E1DF3E1E6A8

Q37225747-7A57F978-5377-45F0-AF22-F83FF5237AE4

Q37225747-AFBABA4D-8FE5-4DFE-81AA-0415902C80F9

Q37225747-E2098698-0CE2-4FC7-8965-955ACB262E43

Q37225747-EA80B7FD-E7EC-4AC6-AE5E-D4112660B320

Q37225747-F1F38E0E-3BDD-4CA0-9AC5-012415571844

P2860

Q37225747-07B68839-F9B2-414C-ADC3-5CFF9A35AB01

Q37225747-106207F1-8449-4E1A-A3F7-1D4BA80201C8

Q37225747-10A49E21-27BD-4202-B60F-3B6DC766F214

Q37225747-170CE2B1-0385-41A7-9AFF-FC3F825E61CC

Q37225747-2B2130DB-A406-4C43-A3D0-CC3A7A347839

Q37225747-4D522586-083B-43FF-8CE3-79CF77EF0CF5

Q37225747-5EDF207D-32C5-48E8-A2AB-89B3882606D9

Q37225747-69F32FCF-2365-4E05-A902-156AC9419860

Q37225747-74A8AE08-7C7A-4871-B888-328D8E40E2B7

Q37225747-78B951E2-2196-4901-835A-EC6E69B87B0E

P2888

Q37225747-EE0EB958-59B6-4E72-9987-E318C5A5EB66

P304

Q37225747-23B924BA-5791-4974-AE5F-972BA35FA1E5

P31

Q37225747-48058F72-7542-47C6-957A-1B4E24DC35F9

P356

Q37225747-3D51BE8E-22DB-471B-85A4-F0E9625C4120

P407

Q37225747-A621ECEC-6A42-4677-82FB-3C70188D0FE7

P433

Q37225747-00C66998-B9D9-430A-BC5D-7626E1B587C4

P478

Q37225747-ED260A8E-0DDF-43FA-98F3-4105E817463D

P577

Q37225747-3B3A1108-7568-44F5-ADBE-F3C1E36C759C

P5875

Q37225747-7CBB366F-7FF2-4666-88ED-BD6BF03A9A94

P698

Q37225747-8FF8CA0B-1C10-4B43-A69D-454A983C5655

P932

Q37225747-8A6C2929-ABBC-47D6-B2A6-4DF7C14AAE79

P356

P1433

British Journal of Cancer

P1476

Correlation of RET somatic mut ...... medullary thyroid carcinomas.

@en

P2093

A E Pinto

http://www.w3.org/2001/XMLSchema#string

B M Cavaco

http://www.w3.org/2001/XMLSchema#string

J R Santos

http://www.w3.org/2001/XMLSchema#string

M J Bugalho

http://www.w3.org/2001/XMLSchema#string

M M Moura

http://www.w3.org/2001/XMLSchema#string

M O Cid

http://www.w3.org/2001/XMLSchema#string

R Domingues

http://www.w3.org/2001/XMLSchema#string

V Leite

http://www.w3.org/2001/XMLSchema#string

P2860

Multiple endocrine neoplasia type 2

Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B

Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.

A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns]

RET proto-oncogene in the development of human cancer.

Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.

Molecular mechanisms of RET activation in human cancer.

Multiple endocrine neoplasia syndrome: genetic basis for clinical management.

Molecular genetics of multiple endocrine neoplasia types 1 and 2.

RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors.

P2888

P304

1777-1783

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6605056

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

100

http://www.w3.org/2001/XMLSchema#string

P577

2009-04-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24376593

http://www.w3.org/2001/XMLSchema#string

P698

19401695

http://www.w3.org/2001/XMLSchema#string

P932

2695700

http://www.w3.org/2001/XMLSchema#string